Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Traumatic Brain Injury
NCT05018832Phase 1Not yet recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2026
- Primary completion
- Nov 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in traumatic brain injury (TBI), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Adverse Events at 48 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT05018832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018832.